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ABSTRACT
Background and Object: Whether opioid-receptor mu 1 (OPRM1) A118G 
polymorphism (rs1799971) is associated with nicotine dependence is controversial. 
We analyzed the combined results from published studies of this possibility.
Methods: Literature reviews were performed according to Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Web of 
Science, Chinese National Science Infrastructure (CNKI), PubMed, Embase and 
Google Scholar database searches using MeSH terms were conducted to find all 
relevant researches up to October 2016. Odds ratios (ORs) and their 95% confidence 
intervals (95% CIs) were calculated in allele, homozygote, heterozygote, dominant 
and recessive models. Ethnicity-specific subgroup meta-analysis, heterogeneity, 
sensitivity analysis and publication bias were considered.
Results: Seven eligible studies with 3313 patients were included. The ORs in the 
five genetic models mentioned above were 1.000 (95% CI: 0.906, 1.104; p = 0.999), 
1.032 (95% CI: 0.771, 1.381; p = 0.834), 0.963 (95% CI: 0.799, 1.162; p = 0.696), 
1.006 (95% CI: 0.916, 1.104; p = 0.907), 0.967 (95% CI: 0.715, 1.309; p = 0.830), 
respectively. Only in dominant model is the association significant. Upon ethnicity-
specific subgroup analysis, there is no statistical significance.
Conclusion: OPRM1-A118G polymorphism (A>G) is not associated with nicotine 
dependence.
INTRODUCTION
Nicotine dependence is one of the commonest 
behavioral disorders. It involves psychological and physical 
dependences on nicotine and loss of control of in spite 
of frequent undesirable complications [1]. Smoking is 
considered to be one of the independent causes of a series of 
severe illnesses such as stroke, pulmonary disease, cardiac-
cerebral vascular disease, and cancer. In recent years, some 
studies implicate genetic factors in the susceptibility to 
smoking addiction [2, 3]. A number of candidate genes in 
the reinforcement and reward system may play vital roles 
in drug abuse, including that of nicotine dependence [4].
A significant neurotransmitter system relevant to 
nicotine-induced reward is the endogenous opioid system. 
Nicotine consumption can lead to increased endogenous 
opioids, especially β-endorphin. The binding of β-endorphin 
to μ-opioid receptors (genetic locus OPRM1) might 
reinforce nicotine dependence by increasing dopamine 
actions in reward centers [5, 6]. As suspected in the case 
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of alcohol, genetic variations of OPRM1 might impact the 
risk of developing nicotine dependence. The exon 1 A118G 
(rs1799971) is in the OPRM1 coding area, leading to an 
Asn40Asp substitution of amino acids. Present studies of 
the possible association of nicotine dependence and 
OPRM1-A118G polymorphism evince mixed findings. 
Present studies are of small sample size, and we therefore 
performed a meta-analysis of the available case-controlled 
trials.
RESULTS
Search results and study features
Figure 1 outlines the literature search process. Based 
on the inclusion criteria set in Table 1, a total of seven 
articles involving 3313 patients were finally included 
[5, 7–11], among which four studies [5, 7, 10] involved 
predominantly white patients in the USA, Norway, and 
Spain (1596 cases in total). Three involved predominantly 
Asian patients [8, 9, 11] in mainland China [9, 11] and 
Taiwan [8] (1717 cases in total). All studies were reported 
in English. Nicotine dependence was defined by nicotine 
consumption and smoking history. In all included studies, 
distributions of the OPRM1-A118G polymorphism (A>G) 
in the controls were consistent with Hardy-Weinberg 
equilibrium. A variety of genotyping methods were 
applied including PCR-RFLP [8, 10], iPLEX/MALDI-
TOF mass spectrometry [9], and TaqMan assay method 
[5, 7, 10, 11]. Genes were read from blood samples in all 
included studies. Controls were mainly matched in terms 
of age, and they were population-based in four studies 
[5, 7, 9, 10], hospital-based in two [10], and not so-
specified in two [8, 11]. Literature methodological quality 
assessment scoring standard is shown in Table 2), and the 
explanations of some key statistical concepts are shown 
in Table 3. Study characteristics and quality assessment 
results are shown in Table 4.
Meta-analysis results
The main results including heterogeneity tests, 
effect models adopted accordingly, and the pooled OR 
with 95% CI and P value of this meta-analysis were shown 
in Table 5. The Labbe plots for allele model, heterozygote 
model and dominant model were shown in Figure 2A, 
2B, 2C. In the overall level, the statistically correlation 
between OPRM1-A118G polymorphism and increased 
nicotine-dependence risks was not found in any of the five 
models (allele model: OR 1.000, 95% CI 0.906, 1.104; 
p = 0.999; Figure 3A; homozygote model: OR 1.032, 
95% CI 0.771, 1.381; p = 0.834; Figure 3B; heterozygote 
model: OR 0.963, 95% CI 0.799, 1.162; p = 0.696; Figure 
3-C; dominant model: OR 1.006, 95% CI 0.916, 1.104; p 
= 0.907; Figure 3D; recessive model: OR 0.967, 95% CI 
0.715, 1.309; p = 0.830; Figure 3E).
Since ethnicity may have effect on this association, 
ethnicity-specific subgroup analysis was also performed. 
All ethnicities involved in these 7 articles can be divided 
into Caucasian group and Asian group. The subgroup 
results of heterogeneity tests and meta-analysis were also 
shown in Table 5 and Figure 3, from which, neither in 
Caucasian group nor in Asian group, the OPRM1-A118G 
polymorphism has correlation to nicotine-dependence. So 
at least for now, we cannot provide the evidence for the 
correlation based on the current circumstance.
Sensitivity-analyses and publication-bias
The sensitivity-analyses suggested that the final 
OR was not influenced by removing each single literature 
(Figure 2D-2F). Funnel plots showed the overall symmetric 
distributions of the studies (Figure 2G-2I), indicating less 
likelihood of publication-bias. Meanwhile, according to 
Egger’s test results, no significant publication bias was 
suggested for these included studies (p > 0.05, Table 5).
DISCUSSION
In consideration of the significance of μ-opioid 
receptor systems in physiological mechanisms about the 
reward center, biologically, it is plausible that OPRM1 
polymorphisms can modulate the risks of nicotine-
dependence. Previously published reports demonstrated 
that OPRM1 A118A mRNAs were 1.5 to 2.5 folds more 
abundant than 118G mRNAs in cerebral homogenate, and 
118G could lead to a 10 folds reduction at OPRM1-protein 
levels [12]. This indicated that the OPRM1-A118G was 
a functional allelic variant with damaging effect on both 
mRNA and protein production.
In the recent years, big data has established very 
close associations between OPRM1-A118G polymorphism 
and nicotine, alcohol, and opioid-dependence. Kapur et 
al. and Tan et al. found a positive correlation between the 
OPRM1-A118G polymorphism and heroin-dependences 
[13, 14]. Altered modulations of kinase A are considered 
to be responsible for the correlations [15]. Recently, 
Frances et al. found that OPRM1-A118G polymorphism 
(A>G) is closely related to alcohol/tobacco-dependence in 
Spanish people, and this association was affected by some 
environmental and genetic factors [5]. In females, Ray 
et al. found that there might be significant associations 
between nicotine reinforcements and the OPRM1-A118G 
haplotype [16]. Zhang and colleagues thought that it was 
some other markers combined within A1118G that were 
significantly associated with smoking initiation, instead 
of single OPRM1-A118G variant [11]. They found that 
another allele near the A118G locus serves as the actual 
risk factor [11]. Genome-wide association researches also 
showed that the OPRM1 gene is closely related to nicotine 
dependence [17].
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A single study cannot confirm the correlation between 
OPRM1-A118G polymorphism and nicotine-dependence 
risks convincingly. This is particularly true for researches 
with relatively small sample-sizes. Given this, we pooled 
several databases to analyze the associations between 
nicotine-dependence and the OPRM1-A118G polymorphism. 
In our study, the statistically correlation between OPRM1-
A118G polymorphism and increased nicotine-dependence 
risks was not detected in any of the five genetic models 
(OR 1.261, 95% CI 1.008, 1.578; p = 0.042). Also, different 
ethnicities might contribute to variable association findings. 
Thus, we also performed an ethnicity-based subgroup 
analysis. Similarly, no matter for Caucasian population or 
Asian population, the OPRM1-A118G polymorphism has no 
Figure 1: Literature search and selection of articles. 
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Table 1: Inclusion criteria for study selection in this meta-analysis
Number Inclusion criteria
1 Case-control studies.
2 The studies evaluated the associations between OPRM1 A118G polymorphism and nicotine dependence.
3 The studies included detailed genotyping data (total number of cases and controls, number of 
cases and controls with A/A, A/G, and G/G genotypes).
4 Studies focusing on human being.
Number Exclusion criteria
1 The design of the experiments was not case-control.
2 The source of cases and controls, and other essential information were not provided.
3 The genotype distribution of the control population was not in accordance with the Hardy–
Weinberg equilibrium (HWE).
4 Reviews and duplicated publications.
Figure 2: Labbe plots, sensitivity analysis plots and contour-enhanced funnel plots of the included studies focusing 
on the association between OPRM1-A118G Polymorphism and nicotine-dependence risk. Labbe plots in allele model (A), 
heterozygote model (B), and dominant model (C). Sensitivity analysis in allele model (D), heterozygote model (E), and dominant model 
(F). Funnel plots in allele model (G), heterozygote model (H), and dominant model (I).
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Table 3: Statistical methods used in this meta-analysis and their explanations
Statistic means Goals and usages Explanation
Labbe plot
To evaluate heterogeneity between the 
included studies
In Labbe figure, if the points basically present as a linear 
distribution, it can be taken as an evidence of homogeneity.
Cochran’s Q test
To evaluate heterogeneity between the 
included studies
Cochran's Q test is an extension to the McNemar test 
for related samples that provides a method for testing 
for differences between three or more matched sets 
of frequencies or proportions. Heterogeneity was also 
considered significant if P < 0.05 using the Cochran's Q test.
I2 index test To evaluate heterogeneity between the included studies
The I2 index measures the extent of true heterogeneity dividing 
the difference between the result of the Q test and its degrees 
of freedom (k – 1) by the Q value itself, and multiplied by 100. 
I2 values of 25%, 50% and 75% were used as evidence of low, 
moderate and high heterogeneity, respectively.
Sensitivity analysis To examine the stability of the pooled results
A sensitivity analysis was performed using the one-at-a-time 
method, which involved omitting one study at a time and 
repeating the meta-analysis. If the omission of one study 
significantly changed the result, it implied that the result 
was sensitive to the studies included.
Funnel plot Publication bias test
In the absence of publication bias, it assumes that studies with 
high precision will be plotted near the average, and studies 
with low precision will be spread evenly on both sides of 
the average, creating a roughly funnel-shaped distribution. 
Deviation from this shape can indicate publication bias.
Table 2: Scale for methodological quality assessment
Criteria Score
1. Representativeness of cases
 RA diagnosed according to acknowledged criteria. 2
 Mentioned the diagnosed criteria but not specifically described. 1
 Not Mentioned. 0
2. Source of controls
 Population or community based 3
 Hospital-based RA-free controls 2
 Healthy volunteers without total description 1
 RA-free controls with related diseases 0.5
 Not described 0
3. Sample size
 >300 2
 200-300 1
 <200 0
4. Quality control of genotyping methods
 Repetition of partial/total tested samples with a different method 2
 Repetition of partial/total tested samples with the same method 1
 Not described 0
5. Hardy-Weinberg equilibrium (HWE)
 Hardy-Weinberg equilibrium in control subjects 1
 Hardy-Weinberg disequilibrium in control subjects 0
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Figure 3: Forest plots (individual and pooled effects with 95% CI) regarding the association between OPRM1-A118G polymorphism and 
nicotine-dependence in allele model (A), homozygote model (B), heterozygote model (C), dominant model (D) and recessive model (E).
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correlation to nicotine-dependence in all there five genetic 
models. Regarding the testing statistic, the integrated ORs 
were calculated. Generally, relative risk (RR) and OR are 
usually comparable in magnitude if the studied diseases 
are rare, like this case. However, using RR can sometimes 
magnify or overestimate risks, especially if the diseases are 
with higher incidence. We carefully reviewed our manuscript 
and related articles and we are happy to say in our meta-
analysis, OR for study outcomes are comparable as RRs 
and these additional data is adding value to estimate a more 
accurate effect. In our meta-analysis, no publication bias was 
suggested according to the funnel-plot. We also conducted the 
Egger’s test [18]. All p values were more than 0.05, indicating 
there was no significant publication bias.
There may be some limitations in our meta-analysis. 
Firstly, the number of the included literatures and the 
sample-size for each ethnicity were limited. Hence, type-
II error couldn’t be dismissed. Secondly, the effect of 
gene-environment interactions and gene-gene interactions 
was not emphasized because not all researches had this 
information, or even when they did, adjusted factors 
were reported differently. Thirdly, more accurate ORs 
should be adjusted by patient factors such as gender, age, 
living styles, medication consumption and other exposure 
factors. Fourth, only published articles were included, the 
unpublished and ongoing studies could convert our result.
MATRIALS AND METHODS
Publication search and selection criteria
Two authors searched Chinese National Knowledge 
Infrastructure (CNKI), Web of Science, PubMed, Embase 
and Google Scholar independently (cut-off date: 30 October 
2016) to include case control researches about the correlation 
between the polymorphism of OPRM1-A118G (rs1799971) 
and nicotine-dependence risks. Search terms include 
“nicotine or tobacco or smoking” and “rs1799971 or A118G 
or OPRM1”. Relevant references were also searched to 
identify other potentially available researches. The inclusion-
criteria and the exclusion-criteria are shown as Table 1.
Data extraction
According to the inclusion criteria set in Table 1, 
two independent authors reviewed and extracted the 
Table 5: Results of meta-analysis for various genotype models
Genetic model Heterogeneity test Test of Association Egger’s test
Name Explanation Ethnicity Q value d.f. I-squared Tau-squared P Value Heterogeneity Effect 
model
Pooled 
OR
95% CI Z value P value Statistical 
significance
P Value 95% CI Publication 
bias
Allele model G vs. A
Caucasian 5.70 3 47.3% NA 0.127 No Fixed 0.876 [0.719, 1.067] 1.32 0.187 No - - -
Asian 0.31 2 0.0% NA 0.857 No Fixed 1.056 [0.943, 1.183] 0.94 0.346 No - - -
Total 8.02 6 25.2% NA 0.236 No Fixed 1.000 [0.906, 1.104] 0.00 0.999 No 0.174 [-4.45, 1.05] No
Homozygote 
model GG vs. AA
Caucasian 3.54 3 15.3% NA 0.315 No Fixed 1.062 [0.439, 2.566] 0.13 0.895 No - - -
Asian 0.57 2 0.0% NA 0.751 No Fixed 1.027 [0.756, 1.395] 0.17 0.867 No - - -
Total 4.07 6 0.0% NA 0.667 No Fixed 1.032 [0.771, 1.381] 0.21 0.834 No 0.768 [-1.69, 1.32] No
Heterozygote 
model AG vs. AA
Caucasian 9.92 3 69.8% 0.1140 0.019 Yes Random 0.797 [0.530, 1.197] 1.10 0.273 No - - -
Asian 0.16 2 0.0% 0.0000 0.923 No Fixed 1.112 [0.984, 1.256] 1.70 0.089 No - - -
Total 14.66 6 59.1% 0.0332 0.023 Yes Random 0.963 [0.799, 1.162] 0.39 0.696 No 0.228 [-7.24, 2.20] No
Dominant 
model AG+GG vs. AA
Caucasian 7.30 3 58.9% NA 0.063 No Fixed 0.862 [0.715, 1.039] 1.55 0.120 No - - -
Asian 0.15 2 0.0% NA 0.928 No Fixed 1.080 [0.971, 1.200] 1.42 0.157 No - - -
Total 11.02 6 45.5% NA 0.088 No Fixed 1.006 [0.916, 1.104] 0.12 0.907 No 0.195 [-6.22, 1.65] No
Recessive 
model GG vs. AA+AG
Caucasian 3.92 3 23.5% NA 0.270 No Fixed 1.133 [0.473, 2.711] 0.28 0.779 No - - -
Asian 0.58 2 0.0% NA 0.748 No Fixed 0.941 [0.682, 1.297] 0.37 0.710 No - - -
Total 4.29 6 0.0% NA 0.638 No Fixed 0.967 [0.715, 1.309] 0.21 0.830 No 0.984 [-1.53, 1.51] No
Table 4: Characteristics of studies included in the meta-analysis
Author Year Country Ethnicity Disease type Genotyping Source of controls Nicotine-dependence (n) Controls (n) P for 
HWE
Quality
Total AA AG GG Total AA AG GG
Schinka 2002 USA Caucasian Nicotine -dependence PCR-RFLP Population-based 134 114 20 0 297 220 73 4 0.0000 8
Zhang 2006 China Asian Nicotine -dependence Taqman NA 443 343 90 10 238 187 46 5 0.313 8
Chen 2013 Taiwan, China Asian Nicotine -dependence PCR-RFLP NA 366 151 170 45 387 180 159 48 0.1678 6
Fang 2014 China Asian Nicotine -dependence iPLEX/MALDI-TOF mass spectrometry Population-based 137 64 62 11 146 72 58 16 0.4116 7
Hasvik 2014 Norway Caucasian Nicotine -dependence Taqman Population-based 43 34 9 0 75 61 13 1 0.7484 6
Frances 2015 Spain Caucasian Nicotine -dependence Taqman Population-based 175 118 54 3 588 408 166 14 0.549 8
Hirasawa 2015 USA Caucasian Nicotine -dependence Taqman Hospital-based 196 157 29 10 88 63 25 0 0.1204 7
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needed data and information from the included articles. 
We collected the following information: author names, 
publication years, countries, ethnicities (Asian, Caucasian 
or others), genotyping ways, total numbers of respondents, 
numbers of controls and cases with OPRM1-A118G 
polymorphism, numbers of controls and cases with G/G, 
A/G and A/A genotype, control source (hospital-based or 
population-based), and P-value regarding Hardy-Weinberg 
equilibrium (HWE).
Quality assessment
In accord with the methodological quality-
assessment scale (see Table 2), that was adjusted from 
a previous publication, 2 authors estimated the qualities 
of the included literatures independently. Disagreement 
would be solved by discussion. In this methodological 
quality assessment scale, five items, including quality 
controls of genotyping ways, source of controls, sample 
sizes, cases representativeness and HWE were prudently 
checked. The quality scores range from 0 to 10, and high 
scores indicate good quality.
Statistical analyses
This meta-analysis was in accordance with the 
PRISMA guidelines and checklists [19]. HWE in each study 
was firstly assessed, followed by the calculation of ORs 
with 95% CIs reflecting the correlation strength between 
OPRM1-A118G polymorphisms and the risks of nicotine-
dependence. The integrated ORs were calculated and used 
for comparisons respectively in allele model (G vs. A), 
homozygote model (GG vs. AA), heterozygote model (AG 
vs. AA), dominant model (AG + GG vs. AA), and recessive 
model (GG vs. AA + AG). Ethnicity-specific subgroup 
(Caucasian and Asian) meta-analysis was also performed. 
The Labbe plot, I2 test and Cochran's Q-test (Table 3) were 
done for accessing the heterogeneities [20]. If no evidences 
of heterogeneities were suggested, the fixed-effects model 
would be chosen [21]. Otherwise, we chose the random-
effects model. To access the stability, sensitivity-analyses 
are also necessary (explanation in Table 3) [22]. Using 
funnel plots and Egger linear regression tests (Table 3), 
potential publication biases were calculated. P < 0.05 
indicates statistical significance.
CONCLUSIONS
Opioid Receptor mu 1 (OPRM1) A118G 
Polymorphism (rs1799971) is not associated with nicotine 
dependence in white or Asian populations.
Abbreviations
OPRM1 = Opioid Receptor mu 1, CNKI = Chinese 
National Science Infrastructure, OR = odds ratio, CI 
= confidence interval, PCR-RFLP = Polymerase chain 
reaction restriction fragment length polymorphism, RR = 
relative risk.
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